Vericel Corp - Company Profile
Powered by 
All the data and insights you need on Vericel Corp in one report.
$295
- Save hours of research time and resources with
our up-to-date Vericel Corp Strategy Report
- Understand Vericel Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Business Description
Vericel Corp (Vericel) is a developer of patient-specific expanded cell therapies for sports medicine and burn care sectors. It markets two FDA-approved cell therapy products: MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts).
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Vericel’s R&D activities focus on cell therapies for certain clinical indications and to decrease the manufacturing cost of products. It emphasizes cell culture surface and media modification, tissue procurement and processing, and other process efficiencies. In FY2022, the company spent US$19.9 million on its R&D activities and increased 22.4% YoY. It comprises of one issued patent in the US related to MACI and one pending application in both European Union and the US.
Product Categories
Overview
Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of adults and pediatric patients with severe deep-dermal or full-thickness burns comprising greater than or equal to 30% of total body surface area. -Manufactures product by isolating and expanding keratinocytes obtained from patient’s healthy skin. Intends to increase the revenue by increasing the number of burn centers consistently using Epicel.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
MACI (autologous cultured chondrocytes on porcine collagen membrane) is a US FDA approved autologous cellularized scaffold indicated for the repair of symptomatic, full-thickness cartilage defects of the knee in adult patients. - Manufactures MACI from autologous cultured chondrocytes (human-derived cells) obtained from the patient's cartilage. Seeks to increase the company sales by increasing the number of surgeons implanting MACI and the average number of implants per surgeon.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
NexoBrid (concentrate of proteolytic enzymes enriched in bromelain), a treatment for nonviable burn tissue, or eschar, in patients with deep partial and full-thickness thermal burns. - The product is approved in European Union and other international markets and designated as an orphan biologic in European Union, the US and other international markets. -Focus on commercializing and marketing NexoBrid for burn patients requiring debridement.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer